Rapid risk assessment: Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae
This risk assessment will discuss CAZ-AVI resistance in brief, review the recent literature reporting resistance of CRE to CAZ-AVI, and assess the risk for the EU/EEA countries.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae - first update
This update of the 2016 ECDC Rapid Risk Assessment on carbapenem-resistant Enterobacteriaceae (CRE) evaluates the risk for patients and healthcare systems in EU/EEA countries due to the global spread of CRE.
Communicable Disease Threats Report, 27 May - 2 June 2018, week 22
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 27 May - 2 June 2018 and includes updates on dengue, ebola virus disease, yellow fever, Cholera, monitoring environmental suitability of Vibrio growth in the Baltic Sea, Nipah virus disease, West Nile virus, Salmonella Agona, Rapid emergence of resistance to new antibiotic. β-lactamase inhibitor combination Ceftazidime-Avibactam.
Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia
This rapid risk assessment aims to assess the risk of XDR Neisseria gonorrhoeae spreading further in the EU/EEA and provide some options for response.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2016
This report covers data on antimicrobial resistance in zoonotic and indicator bacteria in 2016, submitted by 28 EU Member States. Resistance in bacterial isolates of zoonotic Salmonella and Campylobacter from humans, animals and food, and resistance in indicator Escherichia coli as well as in meticillin-resistant Staphylococcus aureus from animals and food were addressed and analysed jointly by ECDC and EFSA.
ECDC country visit to Spain to discuss antimicrobial resistance issues
On 15-19 February 2016 an ECDC team conducted visits and meetings to discuss AMR issues in Spain, with the overall objective of providing an evidence-based assessment of the situation in Spain. The AMR situation in Spain poses a major public health threat to the country. Antimicrobial consumption in primary care and hospitals is among the highest in the EU/EEA and infection prevention and control and environmental cleaning measures vary significantly among hospitals and units.
ECDC country visit to Italy to discuss antimicrobial resistance issues
An ECDC team conducted visits and meetings to Italy on 9-13 January 2017 to specifically discuss and assess the situation in the country regarding prevention and control of AMR.
Observations from this ECDC country visit confirm that the AMR situation in Italian hospitals and regions poses a major public health threat to the country. If the current trends of carbapenem resistance and colistin resistance in gram-negative bacteria such as Klebsiella pneumoniae and A. baumannii are not reversed, key medical interventions will be compromised in the near future.
ECDC country visit to Luxembourg to discuss antimicrobial resistance issues
An ECDC team conducted visits and meetings to the country on 29 May - 2 June 2017, with the objective of providing an evidence-based assessment of the situation. Antibiotic consumption in Luxembourg is at the EU average in hospitals, but higher than the EU average in the community. The AMR levels in bacterial isolates from humans are at or below the EU average.